AU2019212480B2 - Human antibodies to influenza hemagglutinin - Google Patents
Human antibodies to influenza hemagglutininInfo
- Publication number
- AU2019212480B2 AU2019212480B2 AU2019212480A AU2019212480A AU2019212480B2 AU 2019212480 B2 AU2019212480 B2 AU 2019212480B2 AU 2019212480 A AU2019212480 A AU 2019212480A AU 2019212480 A AU2019212480 A AU 2019212480A AU 2019212480 B2 AU2019212480 B2 AU 2019212480B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- influenza
- binding
- antigen
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622480P | 2018-01-26 | 2018-01-26 | |
| US62/622,480 | 2018-01-26 | ||
| PCT/US2019/015029 WO2019147867A1 (en) | 2018-01-26 | 2019-01-24 | Human antibodies to influenza hemagglutinin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019212480A1 AU2019212480A1 (en) | 2020-09-10 |
| AU2019212480B2 true AU2019212480B2 (en) | 2025-07-24 |
Family
ID=66286952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019212480A Active AU2019212480B2 (en) | 2018-01-26 | 2019-01-24 | Human antibodies to influenza hemagglutinin |
Country Status (17)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7611908B2 (ja) * | 2019-10-28 | 2025-01-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗血球凝集素抗体およびその使用方法 |
| WO2021202235A1 (en) * | 2020-04-01 | 2021-10-07 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| KR20230135569A (ko) * | 2020-11-23 | 2023-09-25 | 비르 바이오테크놀로지, 인코포레이티드 | 인플루엔자 a 바이러스에 대한 항체 |
| EP4508077A4 (en) | 2022-04-14 | 2026-03-25 | Invisishield Tech Ltd | COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS |
| KR102835659B1 (ko) * | 2024-11-28 | 2025-07-24 | 주식회사 마크헬츠 | 인플루엔자 a형 바이러스 검출용 항체 및 이의 용도 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051010A1 (en) * | 2013-10-02 | 2015-04-09 | Medimmune, Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| EP3011968A1 (en) * | 2013-03-29 | 2016-04-27 | Celltrion, Inc. | Composition comprising at least two influenza a virus-neutralizing-binding molecules |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP2008539785A (ja) * | 2005-05-16 | 2008-11-20 | モルフォテック、インク. | 所望の表現型を示す細胞を選択するために制御されたベクター |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| EP1947423A1 (en) | 2007-01-16 | 2008-07-23 | Sony Deutschland Gmbh | Distance, orientation and velocity sensitive controller |
| JP5597128B2 (ja) | 2007-05-11 | 2014-10-01 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | H5トリインフルエンザの診断および監視に有用なh5亜型特異的結合タンパク質 |
| US8383121B2 (en) | 2007-09-13 | 2013-02-26 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
| JP5490695B2 (ja) | 2007-09-13 | 2014-05-14 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | インフルエンザウイルスh5亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用 |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| JP5490725B2 (ja) | 2008-02-05 | 2014-05-14 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | H5亜型インフルエンザウイルスの普遍的な検出のための結合タンパク質およびエピトープブロッキングelisa |
| CA2719201A1 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc. | Neutralizing molecules to viral antigens |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
| AU2008365616A1 (en) | 2008-12-24 | 2011-08-11 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof |
| EP2380976A4 (en) | 2008-12-25 | 2012-11-07 | Univ Osaka | HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS |
| KR101790354B1 (ko) | 2009-05-11 | 2017-10-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 h3n2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도 |
| US20120128671A1 (en) | 2009-05-13 | 2012-05-24 | Lawrence Horowitz | Neutralizing molecules to influenza viruses |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| CN102791734B (zh) | 2010-03-08 | 2014-10-15 | 赛特瑞恩股份有限公司 | 源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体 |
| RU2635999C2 (ru) | 2010-06-17 | 2017-11-17 | ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи | Антитела, подходящие для пассивной иммунизации против гриппа |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| WO2012045001A2 (en) | 2010-09-30 | 2012-04-05 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
| EP2731967B1 (en) | 2011-07-14 | 2016-10-12 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| ITRM20110606A1 (it) | 2011-11-16 | 2013-05-17 | Ist Superiore Sanita | Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza. |
| WO2013081463A2 (en) | 2011-12-02 | 2013-06-06 | Aimm Therapeutics B.V. | Influenza a virus specific antibodies |
| MX367743B (es) | 2011-12-05 | 2019-09-04 | Trellis Bioscience Llc | Anticuerpos utiles para la inmunizacion pasiva de influenza. |
| MX360056B (es) | 2012-03-08 | 2018-10-19 | Janssen Vaccines & Prevention Bv | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| BR112015010817A8 (pt) | 2012-11-13 | 2018-01-23 | Genentech Inc | anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AU2015214146B2 (en) | 2014-02-04 | 2020-09-17 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| MX2016012530A (es) | 2014-03-27 | 2017-01-05 | Genentech Inc | Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. |
| CN104031118B (zh) | 2014-06-19 | 2016-04-13 | 天津大学 | 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法 |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10435462B2 (en) | 2015-03-31 | 2019-10-08 | Viro Dynamics Corporation | Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza |
| US11135282B2 (en) | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| MX389708B (es) | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2020221450A1 (en) | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies and methods for treatment of influenza a infection |
-
2019
- 2019-01-24 SG SG11202006379UA patent/SG11202006379UA/en unknown
- 2019-01-24 CN CN201980009873.XA patent/CN111670195B/zh active Active
- 2019-01-24 WO PCT/US2019/015029 patent/WO2019147867A1/en not_active Ceased
- 2019-01-24 CA CA3088194A patent/CA3088194A1/en active Pending
- 2019-01-24 BR BR112020014849-0A patent/BR112020014849A2/pt not_active IP Right Cessation
- 2019-01-24 AU AU2019212480A patent/AU2019212480B2/en active Active
- 2019-01-24 US US16/964,579 patent/US11780907B2/en active Active
- 2019-01-24 EP EP19719656.1A patent/EP3743442A1/en active Pending
- 2019-01-24 JP JP2020539709A patent/JP7372925B2/ja active Active
- 2019-01-24 MX MX2020007772A patent/MX2020007772A/es unknown
- 2019-01-24 KR KR1020207022064A patent/KR102820941B1/ko active Active
- 2019-01-24 IL IL275884A patent/IL275884B2/en unknown
- 2019-01-24 EA EA202091563A patent/EA202091563A1/ru unknown
- 2019-01-24 MA MA051681A patent/MA51681A/fr unknown
-
2020
- 2020-07-07 PH PH12020551051A patent/PH12020551051A1/en unknown
- 2020-07-17 CL CL2020001884A patent/CL2020001884A1/es unknown
- 2020-07-23 CO CONC2020/0009043A patent/CO2020009043A2/es unknown
-
2023
- 2023-02-28 JP JP2023030129A patent/JP2023060018A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3011968A1 (en) * | 2013-03-29 | 2016-04-27 | Celltrion, Inc. | Composition comprising at least two influenza a virus-neutralizing-binding molecules |
| WO2015051010A1 (en) * | 2013-10-02 | 2015-04-09 | Medimmune, Llc | Neutralizing anti-influenza a antibodies and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091563A1 (ru) | 2020-10-08 |
| JP7372925B2 (ja) | 2023-11-01 |
| KR20200115517A (ko) | 2020-10-07 |
| JP2023060018A (ja) | 2023-04-27 |
| WO2019147867A1 (en) | 2019-08-01 |
| JP2021511043A (ja) | 2021-05-06 |
| EP3743442A1 (en) | 2020-12-02 |
| CL2020001884A1 (es) | 2020-12-11 |
| CA3088194A1 (en) | 2019-08-01 |
| WO2019147867A9 (en) | 2019-11-07 |
| US20210371505A1 (en) | 2021-12-02 |
| MX2020007772A (es) | 2020-09-18 |
| AU2019212480A1 (en) | 2020-09-10 |
| IL275884A (en) | 2020-08-31 |
| MA51681A (fr) | 2021-05-05 |
| PH12020551051A1 (en) | 2021-08-23 |
| IL275884B2 (en) | 2024-11-01 |
| US11780907B2 (en) | 2023-10-10 |
| CO2020009043A2 (es) | 2020-07-31 |
| KR102820941B1 (ko) | 2025-06-16 |
| BR112020014849A2 (pt) | 2020-12-08 |
| SG11202006379UA (en) | 2020-07-29 |
| IL275884B1 (en) | 2024-07-01 |
| CN111670195B (zh) | 2024-08-13 |
| CN111670195A (zh) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11453714B2 (en) | Human antibodies to influenza hemagglutinin | |
| US10421804B2 (en) | Anti-Zika virus antibodies and methods of use | |
| BR112017015845A2 (en) | antibody, methods for neutralizing infectious ebov, preventing, treating or ameliorating at least one ebov infection symptom or decreasing the frequency or severity of at least one ebov infection symptom and for increasing the survival or likelihood of survival of an individual suffering from ebov infection or an individual exposed to ebov or at risk of ebov exposure or acquisition, pharmaceutical composition, isolated polynucleotide molecule, vector, and cell. | |
| US11780907B2 (en) | Human antibodies to influenza hemagglutinin | |
| AU2025271140A1 (en) | Anti-hemagglutinin antibodies and methods of use thereof | |
| EA046393B1 (ru) | Антитела к гемагглютинину и их применение | |
| EA044791B1 (ru) | Человеческие антитела к гемагглютинину вируса гриппа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |